Biotech Nuvalent unveiled updates on two experimental cancer medicines over the weekend. Analysts say each could be the best ...

Year to date, Nuvalent’s shares have surged 42.4% compared with the industry’s 1.0% growth. During this timeframe, the stock ...

Nuvalent achieved positive data from the phase 1/2 ALKOVE-1 study using NVL-655 for the treatment of patients with ALK-mutant ...

Nuvalent shows promise with strong clinical data for zidesamtinib and NVL-655 in treating ROS1- and ALK-positive NSCLC. Read ...

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the pricing ...

Nuvalent shares are trading lower by 6.2% during Tuesday's session. The company priced a $500 million public offering of 5 million shares at $100 each.

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Nuvalent (NUVL – Research Report) today and set a price target of ...

Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Nuvalent (NUVL – Research Report). The associated price target ...

In terms of valuation, Nuvalent Inc’s market capitalization stands at $7.27 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value.

Shares of Nuvalent NUVL have soared nearly 20% in the past week owing to encouraging updates on its two investigational therapies. Both therapies target previously treated non-small cell lung ...

Nuvalent, Inc. (NASDAQ:NUVL), a company specializing in pharmaceutical preparations, has reported a significant sale of shares by its Chief Scientific Officer, Henry E. Pelish. According to the ...

On Monday, TD Cowen maintained a Buy rating on shares of Nuvalent (NASDAQ:NUVL), following the presentation of updated Phase I data for the company's drugs zidesamtinib and NVL-655. The data ...